Bilateral Chylothorax Complicating a Case of Chronic Lymphocytic Leukemia: A Case Report

LeukemiaLymphoma

Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length

Leuk Lymphoma.

Ammann EM, Shanafelt TD, Wright KB, McDowell BD, Link BK, Chrischilles EA

doi: 10.1080/

Leukemia

Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report

Am J Case Rep.

Lachowiez C, Deodhar A, Kozin E, Spurgeon S

Leukemia

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

J Clin Oncol.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG

doi: 10.1200/JCO.2017.72.8519.

Leukemia

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time

Clin Case Rep.

Molica S, Carillio G, Battaglia C

doi: 10.1002/ccr3.749

Leukemia

Concurrent cerebral aspergillosis and abdominal mucormycosis during Ibrutinib therapy for chronic lymphocytic leukemia

Clin Microbiol Infect.

Pouvaret A, Guery R, Montillet M, Molina TJ, Duréault A, Bougnoux ME, Galliot R, Lanternier F, Delarue R, Lortholary

doi: 10.1016/j.cmi.2019.01.016.

Leukemia

Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review

Am J Case Rep.

Gao X, Li J, Wang L, Lin J, Jin H, Xu Y, Wang N, Zhao Y, Liu D, Yu L, Wang Q

Leukemia

Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia

Australas J Dermatol.

Lee A, Sandhu S, Imlay-Gillespie L, Mulligan S, Shumack S

doi: 10.1111/ajd.12615.

Breast Cancer

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

JAMA Oncol.

Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO

doi: 10.1001/

LeukemiaLymphoma

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach

J Cancer Prev.

Keramatinia A, Ahadi A, Akbari ME, Mohseny M, Jarahi AM, Mehrvar N, Mansouri N, Tabatabaei SAM, Movafagh A

doi: 10.15430/JCP.2017.22.2.74.

Related content

Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length

Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time

Concurrent cerebral aspergillosis and abdominal mucormycosis during Ibrutinib therapy for chronic lymphocytic leukemia

Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review

Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach